Eli Lil­ly re­veals two-year da­ta for ex­per­i­men­tal eczema treat­ment af­ter FDA road­block

Eli Lil­ly is bol­ster­ing the case for its ex­per­i­men­tal eczema treat­ment le­brik­izum­ab with a first look at how pa­tients fared af­ter two years of main­te­nance …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.